LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) presented preliminary results from a clinical trial evaluating its proprietary compound LB-100 in combination with dostarlimab at the 2026 Society of Gynecologic Oncology conference in San Juan, Puerto Rico. The interim data from 20 evaluable patients demonstrated a 40% disease control rate and encouraging survival trends with an acceptable safety profile, supporting continued enrollment of an expanded cohort.
The company is investigating the combination's potential to enhance immunotherapy response in ovarian clear cell carcinoma, a particularly challenging subtype of ovarian cancer. This announcement is significant because ovarian clear cell carcinoma has historically shown poor response to conventional therapies, including immunotherapies, creating an urgent need for more effective treatment options.
LB-100 is LIXTE's lead compound and first-in-class clinical PP2A inhibitor that has demonstrated tolerability in cancer patients at doses associated with anti-cancer activity. According to published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for cancer patients. The compound represents part of a pioneering effort in an entirely new field of cancer biology called activation lethality, which is advancing a new treatment paradigm.
The implications of these interim results extend beyond the immediate patient population. If the combination therapy continues to show efficacy in expanded trials, it could establish a new treatment approach for ovarian clear cell carcinoma and potentially other cancer types resistant to current immunotherapies. The acceptable safety profile reported in these preliminary findings is particularly important, as combination therapies often face challenges with increased toxicity that can limit their clinical utility.
LIXTE's novel approach is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials currently in progress for ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma. Additional information about the company's research can be found at https://www.lixte.com. The company also operates through its wholly owned subsidiary, Liora Technologies Europe Ltd., which is developing electronically controlled proton therapy systems for treating various cancers, with more details available at https://www.lioratechnologies.com.
For investors and the medical community, these interim results provide early validation of LIXTE's approach to enhancing immunotherapy effectiveness through PP2A inhibition. The continued enrollment of an expanded cohort suggests confidence in the preliminary findings and moves the research closer to potentially establishing a new standard of care for patients with ovarian clear cell carcinoma who have limited treatment options.
